Antisense targeting of cFLIP sensitizes activated T cells to undergo apoptosis and desensitizes responses to contact dermatitis

Journal of Investigative Dermatology

Volumn 129, Issue 8, 2009, Pages 1945-1953

  Mourich, Dan V ^a,b   Jendrzejewski, Jessica L ^c   Marshall, Nikki B ^b   Hinrichs, David J ^d   Iversen, Patrick L ^a   Brand, Rhonda M ^c,e  

^a AVI BIOPHARMA INC   (United States)

^b OREGON STATE UNIVERSITY   (United States)

^c Evanston Northwestern Hospital   (United States)

^d PORTLAND VA MEDICAL CENTER   (United States)

^e UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CD4 ANTIGEN; CD8 ANTIGEN; FLICE INHIBITORY PROTEIN; FLUORESCEIN ISOTHIOCYANATE; OLIGOMER; OXAZOLONE;

ANIMAL CELL; ANIMAL MODEL; APOPTOSIS; ARTICLE; CONTACT DERMATITIS; CONTROLLED STUDY; DESENSITIZATION; DOSE RESPONSE; DRUG DOSE INCREASE; DRUG EFFECT; DRUG TOLERABILITY; FEMALE; HYPERSENSITIVITY; LYMPHOCYTIC INFILTRATION; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN TARGETING; T LYMPHOCYTE ACTIVATION;

EID: 67651115933     PISSN: 0022202X     EISSN: 15231747     Source Type: Journal    
DOI: 10.1038/jid.2009.16     Document Type: Article

References (46)

1. Alexeev V, Igoucheva O, Domashenko A, Cotsarelis G, Yoon K (2000) Localized in vivo genotypic and phenotypic correction of the albino mutation in skin by RNA-DNA oligonucleotide. Nat Biotechnol 18:43-7
2. Arora V, Hannah TL, Iversen PL, Brand RM (2002) Transdermal use of phosphorodiamidate morpholino oligomer AVI-4472 inhibits cytochrome P450 3A2 activity in male rats. Pharm Res 19:1465-70
3. Beaulieu MJ, Li H, Bergeron J, Ross G, Auger FA, Rouabhia M (1998) Involvement of male-specific minor histocompatibility antigen H-Y in epidermal equivalent allograft rejection. Cell Transplant 7:11-23
4. Brand RM (2001) Topical and transdermal delivery of antisense oligonucleotides. Curr Opin Mol Ther 3:244-8
5. Brand RM, Iversen PL (1996) Iontophoretic delivery of a telomeric oligonucleotide. Pharm Res 13:851-4
6. Brand RM, Wahl A, Iversen PL (1997) Effects of size and sequence on the iontophoretic delivery of oligonucleotides. J Pharm Sci 87:49-52
7. Chang DW, Xing Z, Pan Y, Algeciras-Schimnich A, Barnhart BC, Yaish-Ohad S et al. (2002) c-FLIP(L) is a dual function regulator for caspase-8 activation and CD95-mediated apoptosis. EMBO J 21:3704-14
8. Cordeiro MF, Mead A, Ali RR, Alexander RA, Murray S, Chen C et al. (2003) Novel antisense oligonucleotides targeting TGF-beta inhibit in vivoscarring and improve surgical outcome. Gene Ther 10:59-71
9. Dajee M, Muchamuel T, Schryver B, Oo A, Alleman-Sposeto J, De Vry CG et al. (2006) Blockade of experimental atopic dermatitis via topical NFkappaB decoy oligonucleotide. J Invest Dermatol 126:1792-803
10. Dokka S, Cooper SR, Kelly S, Hardee GE, Karras JG (2005) Dermal delivery of topically applied oligonucleotides via follicular transport in mouse skin. J Invest Dermatol 124:971-5
11. Dorn A, Ludwig RJ, Bock A, Thaci D, Hardt K, Bereiter-Hahn J et al. (2007) Oligonucleotides suppress IL-8 in skin keratinocytes in vitro and offer anti-inflammatory properties in vivo. J Invest Dermatol 127:846-54
12. Fierz W, Farmer GA, Sheena JH, Simpson E (1982) Genetic analysis of the non-H-2-linked Ir genes controlling the cytotoxic T-cell response to H-Y in H-2d mice. Immunogenetics 16:593-601 Hudziak RM, Barofsky E, Barofsky DF, Weller DL, Huang SB, Weller DD (1996) Resistance of morpholino phosphorodiamidate oligomers to enzymatic degradation. Antisense Nucleic Acid Drug Dev 6:267-72
13. Irmler M, Thome M, Hahne M, Schneider P, Hofmann K, Steiner V et al.(1997) Inhibition of death receptor signals by cellular FLIP. Nature388:190-5
14. Isomura I, Tsujimura K, Morita A (2006) Antigen-specific peripheral tolerance induced by topical application of NF-kappaB decoy oligodeoxynucleotide. J Invest Dermatol 126:97-104
15. Kim YY, Park BJ, Seo GJ, Lim JY, Lee SM, Kimm KC et al. (2003) Long form of cellular FLICE-inhibitory protein interacts with Daxx and prevents Fasinduced JNK activation. Biochem Biophys Res Commun 312:426-33
16. Kirchhoff S, Muller WW, Krueger A, Schmitz I, Krammer PH (2000) TCR-mediated up-regulation of c-FLIPshort correlates with resistance toward CD95-mediated apoptosis by blocking death-inducing signaling complex activity. J Immunol 165:6293-300
17. Krueger A, Baumann S, Krammer PH, Kirchhoff S (2001a) FLICE-inhibitory proteins: regulators of death receptor-mediated apoptosis. Mol Cell Biol21:8247-54
18. Krueger A, Schmitz I, Baumann S, Krammer PH, Kirchhoff S (2001b) Cellular FLICE-inhibitory protein splice variants inhibit different steps of caspase- 8 activation at the CD95 death-inducing signaling complex. J Biol Chem276:20633-40
19. Lashmar UT, Hadgraft J, Thomas N (1989) Topical application of penetration enhancers to the skin of nude mice: a histopathological study. J Pharm Pharmacol 41:118-22
20. Lazou K, Sadick NS, Kurfurst R, Bonnet-Duquennoy M, Neveu M, Nizard C et al. (2007) The use of antisense strategy to modulate human melanogenesis. J Drugs Dermatol 6:s2-7
21. Marshall NB, Oda SK, London CA, Moulton HM, Iversen PL, Kerkvliet NI et al. (2007) Arginine-rich cell-penetrating peptides facilitate delivery of antisense oligomers into murine leukocytes and alter pre-mRNA splicing. J Immunol Methods 325:114-26
22. Mehta RC, Stecker KK, Cooper SR, Templin MV, Tsai YJ, Condon TP et al.(2000) Intercellular adhesion molecule-1 suppression in skin by topical delivery of anti-sense oligonucleotides. J Invest Dermatol 115:805-12
23. Merk HF, Baron JM, Heise R, Fritsche E, Schroeder P, Abel J et al. (2006) Concepts in molecular dermatotoxicology. Exp Dermatol 15:692-704
24. Moulton HM, Moulton JD (2003) Peptide-assisted delivery of steric-blocking antisense oligomers. Curr Opin Mol Ther 5:123-32
25. Nakajima H, Amano W, Fujita A, Fukuhara A, Azuma YT, Hata F et al. (2007) The active site cysteine of the proapoptotic protein glyceraldehyde-3- phosphate dehydrogenase is essential in oxidative stress-induced aggregation and cell death. J Biol Chem 282:26562-74
26. Nolen HWI, Catz P, Friend DR (1994) Research Papers: percutaneous penetration of methyl phosphonate antisense oligonucleotides. Int J Pharm 107:169-77
27. Oldenburg KR, Vo KT, Smith GA, Selick HE (1995) Iontophoretic delivery of oligonucleotides across full thickness hairless mouse skin. J Pharm Sci84:915-21
28. Pannier AK, Arora V, Iversen PL, Brand RM (2004) Transdermal delivery of phosphorodiamidate morpholino oligomers across hairless mouse skin. Int J Pharm 275:217-26
29. Perlman H, Pagliari LJ, Georganas C, Mano T, Walsh K, Pope RM (1999) FLICE-inhibitory protein expression during macrophage differentiation confers resistance to fas-mediated apoptosis. J Exp Med 190:1679-88
30. Regnier V, De Morre N, Jadoul A, Preat V (1999) Mechanisms of a phosphorothioate oligonucleotide delivery by skin electroporation. Int J Pharm 184:147-56
31. Saint-Mezard P, Berard F, Dubois B, Kaiserlian D, Nicolas JF (2004a) The role of CD4+ and CD8+ T cells in contact hypersensitivity and allergic contact dermatitis. Eur J Dermatol 14:131-8
32. Saint-Mezard P, Krasteva M, Chavagnac C, Bosset S, Akiba H, Kehren J et al.(2003) Afferent and efferent phases of allergic contact dermatitis (ACD) can be induced after a single skin contact with haptens: evidence using a mouse model of primary ACD. J Invest Dermatol 120:641-7
33. Saint-Mezard P, Rosieres A, Krasteva M, Berard F, Dubois B, Kaiserlian D et al. (2004b) Allergic contact dermatitis. Eur J Dermatol 14:284-95
34. Sakamoto T, Miyazaki E, Aramaki Y, Arima H, Takahashi M, Kato Y et al.(2004) Improvement of dermatitis by iontophoretically delivered antisense oligonucleotides for interleukin-10 in NC/Nga mice. Gene Ther 11:317-24
35. Schmitz I, Weyd H, Krueger A, Baumann S, Fas SC, Krammer PH et al. (2004) Resistance of short term activated T cells to CD95-mediated apoptosis correlates with de novo protein synthesis of c-FLIPshort. J Immunol172:2194-200
36. Seyfarth F, Elsner P, Tittelbach J, Schliemann S (2008) Contact allergy to mometasone furoate with cross-reactivity to group B corticosteroids. Contact Derm 58:180-1
37. Stein D, Foster E, Huang SB, Weller D, Summerton J (1997) A specificity comparison of four antisense types: morpholino, 20-O-methyl RNA, DNA, and phosphorothioate DNA. Antisense Nucleic Acid Drug Dev7:151-7
38. Summerton J, Weller D (1997) Morpholino antisense oligomers: design, preparation, and properties. Antisense Nucleic Acid Drug Dev 7: 187-95
39. Sun Q, Matta H, Chaudhary PM (2003) The human herpes virus 8-encoded viral FLICE inhibitory protein protects against growth factor withdrawalinduced apoptosis via NF-kappa B activation. Blood 101:1956-61
40. Thome M, Schneider P, Hofmann K, Fickenscher H, Meinl E, Neipel F et al.(1997) Viral FLICE-inhibitory proteins (FLIPs) prevent apoptosis induced by death receptors. Nature 386:517-21
41. Thome M, Tschopp J (2001) Regulation of lymphocyte proliferation and death by FLIP. Nat Rev Immunol 1:50-8
42. Thorburn A (2004) Death receptor-induced cell killing. Cell Signal 16:139-44
43. VanderVegt FP, Johnson LL (1993) Induction of long-term H-Y-specific tolerance in female mice given male lymphoid cells while transiently depleted of CD4+ or CD8+ T cells. J Exp Med 177:1587-92
44. Wang J, Lobito AA, Shen F, Hornung F, Winoto A, Lenardo MJ (2000) Inhibition of Fas-mediated apoptosis by the B cell antigen receptor through c-FLIP. Eur J Immunol 30:155-63
45. Wraight CJ, White PJ (2001) Antisense oligonucleotides in cutaneous therapy. Pharmacol Ther 90:89-104
46. Zhang N, Hopkins K, He YW (2008) The long isoform of cellular FLIP is essential for T lymphocyte proliferation through an NF-kappaBindependent pathway. J Immunol 180:5506-11